Myriad Genetics Files $200M Universal Shelf Registration After Losing Well-Known Seasoned Issuer Status
MYGN sits 18% above its 52-week low of $3.76 on elevated volume (4.9× avg).
Summary
Myriad Genetics filed a $200 million universal shelf registration, replacing a prior filing due to the loss of its "well-known seasoned issuer" status, signaling potential significant dilution amidst recent financial losses.
Key Events · Financing and Capital Events · MYGN
-
Files $200 Million Universal Shelf Registration
The company has registered a variety of securities, including common stock, preferred stock, depositary shares, debt securities, and warrants, for potential future offerings up to an aggregate of $200 million. This is an authorization to sell, not an immediate issuance.
-
Loss of Well-Known Seasoned Issuer (WKSI) Status
This S-3 filing replaces a previous S-3ASR because Myriad Genetics no longer qualifies as a WKSI. This downgrade in status indicates a deterioration in the company's financial standing or market capitalization, making future capital raises potentially more complex and costly.
-
Significant Potential Dilution
The $200 million potential offering represents a substantial portion of the company's current market capitalization, indicating a high likelihood of significant future dilution for existing shareholders if the full amount is raised.
-
Concurrent with Negative Financial Results
This shelf registration is filed on the same day as the company's 10-K, which reported a $365.9 million net loss for 2025, including $319.4 million in goodwill and intangible asset impairments. This context suggests the capital raise is driven by financial necessity.
Analysis · MYGN · Life Sciences
Myriad Genetics has filed a universal shelf registration statement for up to $200 million in various securities, including common stock, preferred stock, debt, and warrants. This filing replaces a prior S-3ASR, as the company is no longer considered a "well-known seasoned issuer" (WKSI) following its recent 10-K filing. The loss of WKSI status is a significant downgrade, indicating a weakened financial position. The potential $200 million capital raise represents a substantial portion of the company's current market capitalization, signaling a high likelihood of future dilution. This comes on the same day as the company reported a significant net loss and impairments for 2025, highlighting an urgent need for capital and potentially challenging financing conditions.
How filings like this one have moved
In the 30 days to Sep 22, 2026, 39.7% of the 335 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.40%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MYGN was trading at $4.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $412.9M. The 52-week trading range was $3.76 to $14.73. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.